食管癌诊断后他汀类药物使用与死亡风险的关联:美国退伍军人的回顾性队列研究
该回顾性队列研究纳入2002至2016年诊断为食管腺癌的7882例和食管鳞状细胞癌的3868例退伍军人患者,分析诊断后他汀使用与死亡风险的关联。结果显示,诊断后他汀使用与食管腺癌和食管鳞状细胞癌患者的癌症特异性死亡及全因死亡风险降低相关,但6个月滞后分析中关联减弱,提示部分效应可能源于反向因果。
要点
- 食管腺癌患者诊断后他汀使用与癌症特异性死亡风险降低相关(HR 0.79,95% CI 0.70-0.88)。
- 食管鳞状细胞癌患者诊断后他汀使用与癌症特异性死亡风险降低相关(HR 0.77,95% CI 0.63-0.92)。
- 6个月滞后分析中关联减弱,提示部分效应可能源于反向因果。
核心结论
- 诊断后他汀使用与食管癌患者死亡风险降低相关,但该效应可能部分源于反向因果,因为预后差的患者不太可能开始他汀治疗。
研究设计与样本
- 回顾性队列研究,纳入2002至2016年VA中央癌症登记处诊断的食管腺癌患者7882例和食管鳞状细胞癌患者3868例。
- 使用时间依赖性Cox回归模型计算死亡风险的风险比(HR)和95%置信区间(CI)。
- 采用时变暴露以避免永生时间偏倚,并设置3个月滞后期(从癌症诊断后3个月开始随访)以减少反向因果。
- 进行敏感性分析,改变癌症诊断日期与随访开始之间的滞后时长。
主要发现
- 诊断后他汀使用记录于27.4%的食管腺癌患者和17.1%的食管鳞状细胞癌患者。
- 食管腺癌患者中,诊断后他汀使用与癌症特异性死亡风险降低相关(HR 0.79;95% CI 0.70-0.88),与全因死亡风险降低相关(HR 0.80;95% CI 0.74-0.86)。
- 食管鳞状细胞癌患者中,诊断后他汀使用与癌症特异性死亡风险降低相关(HR 0.77;95% CI 0.63-0.92),与全因死亡风险降低相关(HR 0.83;95% CI 0.74-0.95)。
- 采用6个月滞后分析时,上述反向关联减弱趋向无效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 效应可能部分源于反向因果,因为预后差的患者不太可能开始他汀治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Statins may reduce mortality from esophageal cancer by both reducing incidence but also improving prognosis. However, prior studies of statin use and mortality have reported conflicting results. METHODS: We identified 7882 patients with esophageal adenocarcinoma (EAC) and 3868 with esophageal squamous cell carcinoma (ESCC) from the VA Central Cancer Registry diagnosed between 2002 and 2016. We identified prescriptions for statins that were filled before and after cancer diagnosis. Time-dependent Cox regression models were used to calculate hazard ratios (HR) and 95% CIs for mortality risk. We used a time-varying exposure to avoid immortal-time bias and a 3 month lag (following patients from 3 months after cancer diagnosis) to reduce reverse causation. A sensitivity analysis was conducted varying the lag duration between date of cancer diagnosis and start of follow-up. RESULTS: Statin use after diagnosis was recorded in 27.4% of EAC and 17.1% of ESCC patients. In EAC patients, statin use after diagnosis was associated with a decreased risk of cancer specific (HR, 0.79; 95% CI 0.70-0.88) and all-cause mortality (HR, 0.80; 95% CI 0.74-0.86). Similarly, statin use after diagnosis of ESCC was associated with a decreased risk of cancer specific (HR, 0.77; 95% CI 0.63-0.92) and all-cause mortality (HR, 0.83; 95% CI 0.74-0.95). The inverse associations were attenuated towards the null with a 6-month lag. CONCLUSIONS: Post-diagnosis statin use was associated with reduced mortality in esophageal cancer patients; however, the effect may be partially due to reverse causality as patients with poor prognosis are unlikely to initiate statin therapy.
引用
- Nguyen T, Khan A, Liu Y, et al. The Association Between Statin Use After Diagnosis and Mortality Risk in Patients With Esophageal Cancer: A Retrospective Cohort Study of United States Veterans. Am J Gastroenterol. 2018. PMID: 29946180. doi:10.1038/s41395-018-0169-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。